Yifan Mao, MSc

Yifan Mao, MSc

Kilpatrick

Contact
View Bio
RSS

Latest Posts › BPCIA

Share:

10 Key Takeaways - Navigating Litigation Under the Biologics Price Competition and Innovation Act BPCIA

On January 11, 2024, Kilpatrick Partner April Isaacson and Counsel Yifan Mao presented “Navigating Litigation Under the Biologics Price Competition and Innovation Act (BPCIA)” to entrepreneurs in the Chinese life science...more

2/7/2024  /  Biosimilars , BPCIA , Competition , Patent Infringement , Patent Litigation , Patents

Drug to Biologic Transition: Is Purple The New Orange?

Approval Processes - The regulatory approval pathway for a new “biological product” submitted as a Biologics License Application (BLA) under the Biologics Price Competition and Innovation Act (BPCIA), is now separate from...more

2/23/2021  /  Biologics , BPCIA , Food and Drug Administration (FDA) , Hatch-Waxman , Orange Book , Patents , Pharmaceutical Industry , Pharmaceutical Patents
2 Results
 / 
View per page
Page: of 1

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
Sign up Log in
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
- hide
- hide